SCHEMBL26599101

SCHEMBL26599101

Fc1c(Br)cccc1CCNC1CC1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
ALOX12 P18054 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TAAR1 Q96RJ0 2/20 0.39
GRIN2B Q13224 3/20 0.37
HTR2A P28223 2/20 0.35
SLC6A2 P23975 1/20 0.35
OPRL1 P41146 1/20 0.34
HTR2C P28335 1/20 0.34
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GRIN1 Q05586 1/20 0.33
SIGMAR1 Q99720 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2468664 0.83 ALDH1A1 (0.47) ALDH1A1MEN1KMT2ALMNAGAA
Formic Acid SCHEMBL5076825 0.76 ALDH1A1 (0.41) ALDH1A1MEN1KMT2ALMNAGAA
SCHEMBL20766279 0.74 SOS1 (0.46) ALDH1A1MEN1KMT2ALMNAGAA
SCHEMBL5988222 0.74 SLC6A4 (0.45) ALDH1A1KMT2ALMNASLC6A2
SCHEMBL26599034 0.72 OPRL1 (0.44) ALDH1A1MEN1KMT2AGRIN2BOPRL1
SCHEMBL18677297 0.72 EPHX2 (0.48) ALDH1A1MEN1KMT2ALMNATAAR1
SCHEMBL1196614 0.72 ALDH1A1 (0.42) ALDH1A1MEN1KMT2AOPRL1
SCHEMBL27885744 0.71 TAAR1 (0.39) TAAR1HTR2AHTR2C
SCHEMBL18733902 0.71 CEL (0.41) GAAL3MBTL1OPRL1
SCHEMBL24822496 0.70 MTNR1A (0.51) ALDH1A1MEN1KMT2ALMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4511355-A2 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FundaMental Pharma GmbH (DE) 2025-02-26 EP disclosed
WO-2023203254-A2 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FUNDAMENTAL PHARMA GMBH (DE) 2023-10-26 WO disclosed